- Report
- September 2021
- 40 Pages
China
From €2481EUR$2,600USD£2,110GBP
- Report
- April 2021
- 50 Pages
China
From €2481EUR$2,600USD£2,110GBP
- Report
- July 2018
- 30 Pages
Global
From €9542EUR$10,000USD£8,117GBP
- Report
- July 2018
- 17 Pages
Global
From €9542EUR$10,000USD£8,117GBP
- Drug Pipelines
- February 2018
- 27 Pages
Global
From €9542EUR$10,000USD£8,117GBP
- Drug Pipelines
- January 2022
- 84 Pages
Global
From €6674EUR$6,995USD£5,678GBP
- Report
- January 2023
- 167 Pages
Global
From €3435EUR$3,600USD£2,922GBP
- Report
- April 2023
- 156 Pages
Global
€4771EUR$5,000USD£4,059GBP
- Report
- April 2023
- 114 Pages
Global
€3340EUR$3,500USD£2,841GBP
- Report
- July 2018
- 20 Pages
Global
From €9542EUR$10,000USD£8,117GBP
- Report
- May 2023
- 85 Pages
Global
From €3500EUR$3,929USD£3,082GBP
- Report
- May 2023
- 81 Pages
Global
From €3500EUR$3,929USD£3,082GBP
- Report
- April 2023
- 96 Pages
Global
From €3500EUR$3,929USD£3,082GBP
- Report
- April 2023
- 95 Pages
Global
From €3500EUR$3,929USD£3,082GBP
- Report
- December 2022
- 210 Pages
Global
From €3521EUR$3,690USD£2,995GBP
Budesonide is a corticosteroid used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. It is available in both inhalation and oral forms, and is used to reduce inflammation in the airways. Budesonide is a synthetic corticosteroid, meaning it is similar to the hormones produced naturally by the body. It works by reducing inflammation in the airways, which helps to reduce symptoms such as wheezing, coughing, and shortness of breath.
Budesonide is a widely used drug in the respiratory market, and is often prescribed as a first-line treatment for asthma and COPD. It is generally well-tolerated and has fewer side effects than other corticosteroids. It is also used in combination with other drugs to treat more severe cases of respiratory diseases.
Some companies in the Budesonide market include AstraZeneca, GlaxoSmithKline, Merck, and Teva Pharmaceuticals. Show Less Read more